OLMA
Olema Pharmaceuticals, Inc.$9.89+0.14 (+1.49%)Prev Close$9.75·MCap$932.9M·P/E—·Vol1.21M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
10
$24.65M
◆
Net Activity
Net Seller
$24.65M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at Olema Pharmaceuticals, Inc. (OLMA) has been exclusively selling, with 0 insider purchases totaling $0.00 and 10 insider sales totaling $24.65M. The most recent insider transaction was by Mitchell Shawnte (officer: CHIEF LEGAL OFFICER), who sold $945.8K worth of shares on Mar 5, 2026. Olema Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $932.9M.
OLMA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | Mitchell Shawnte | officer: CHIEF LEGAL OFFICER | Sell | 39,767 | $23.78 | $945.8K | 233-99% |
| Jan 21, 2026 | Harmon Cyrus | director | Sell | 10,000 | $26.88 | $268.8K | 727,770 |
| Jan 16, 2026 | Harmon Cyrus | director | Sell | 3,489 | $29.12 | $101.6K | 737,770 |
| Jan 15, 2026 | Kovacs Shane William Charles | officer: CH. OPERATING & FINANCIAL OFF. | Sell | 103,822 | $28.70 | $2.98M | 239,727-30% |
| Jan 14, 2026 | Myles David C. | officer: CH. DISCOV. & NON-CLIN DEV OFF | Sell | 110,000 | $28.25 | $3.11M | 577,764 |
| Dec 29, 2025 | Harmon Cyrus | Sell | 2,881 | $28.53 | $82.2K | 741,259 | |
| Dec 23, 2025 | CLARK IAN T | Sell | 264,800 | $29.73 | $7.87M | 234,896-53% | |
| Dec 23, 2025 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 51,000 | $30.46 | $1.55M | 601,656 |
| Dec 23, 2025 | Zojwalla Naseem | Chief Medical Officer | Sell | 269,509 | $27.94 | $7.53M | 116,918-70% |
| Sep 18, 2025 | Harmon Cyrus | Sell | 25,000 | $8.19 | $204.8K | 754,140 | |
| Jan 13, 2025 | Bain Capital Life Sciences Investors, LLC | Buy | 300,000 | $5.76 | $1.73M | 7,800,000 | |
| Dec 17, 2024 | Graham G. Walmsley | Director | Buy | 700,761 | $6.75 | $4.73M0.8% OS | 1,408,875+99% |
| Dec 17, 2024 | Graham G. Walmsley | Director | Sell | 700,761 | $6.75 | $4.73M0.8% OS | 0Exit |
| Dec 11, 2024 | Bohen Sean | PRESIDENT AND CEO | Sell | 109,502 | $9.01 | $986.4K | 298,836-27% |
| Dec 11, 2024 | Harmon Cyrus | Sell | 16,393 | $9.03 | $148.0K | 772,277 | |
| Dec 11, 2024 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 35,159 | $9.01 | $316.7K | 561,905 |
| Dec 11, 2024 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 26,066 | $9.01 | $234.9K | 611,947 |
| Dec 11, 2024 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Sell | 27,805 | $9.01 | $250.5K | 130,031 |
| Aug 5, 2024 | Paradigm Biocapital Advisors LP | 10% Owner | Sell | 2,400,000 | $14.92 | $35.80M2.8% OS | 4,720,482-34% |
| Jul 31, 2024 | Harmon Cyrus | Sell | 5,000 | $15.57 | $77.9K | 752,217 | |
| Jul 12, 2024 | Harmon Cyrus | Sell | 5,000 | $12.26 | $61.3K | 756,283 | |
| Jul 2, 2024 | Harmon Cyrus | Sell | 20,000 | $10.77 | $215.4K | 761,283 | |
| Jun 6, 2024 | Graham G. Walmsley | Director | Sell | 1,175,000 | $14.85 | $17.45M1.3% OS | 708,114-62% |
| Jun 4, 2024 | Harmon Cyrus | Sell | 25,000 | $10.30 | $257.4K | 791,283 | |
| May 7, 2024 | Harmon Cyrus | Sell | 5,000 | $10.92 | $54.6K | 806,283 | |
| May 2, 2024 | Harmon Cyrus | Sell | 15,000 | $9.51 | $142.7K | 811,283 | |
| Mar 29, 2024 | Harmon Cyrus | Sell | 20,000 | $10.97 | $219.4K | 826,283 | |
| Mar 4, 2024 | Harmon Cyrus | Sell | 25,000 | $12.41 | $310.3K | 846,383 | |
| Feb 2, 2024 | Harmon Cyrus | Sell | 30,000 | $12.79 | $383.6K | 876,283 | |
| Jan 2, 2024 | Harmon Cyrus | Sell | 25,000 | $13.38 | $334.5K | 903,783 | |
| Dec 18, 2023 | Graham G. Walmsley | Director | Buy | 640,000 | $10.74 | $6.87M0.7% OS | 1,800,000+55% |
| Dec 8, 2023 | Paradigm Biocapital Advisors LP | 10% Owner | Buy | 100,000 | $11.60 | $1.16M | 6,590,981 |
| Dec 1, 2023 | Harmon Cyrus | Sell | 25,000 | $12.57 | $314.3K | 926,283 | |
| Nov 22, 2023 | Bohen Sean | PRESIDENT AND CEO | Sell | 57,225 | $14.40 | $824.1K | 175,459 |
| Nov 22, 2023 | Harmon Cyrus | Sell | 8,181 | $14.39 | $117.7K | 955,272 | |
| Nov 22, 2023 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 18,742 | $14.39 | $269.7K | 434,832 |
| Nov 22, 2023 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 13,629 | $14.40 | $196.2K | 580,952 |
| Nov 22, 2023 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Sell | 14,556 | $14.38 | $209.3K | 37,959-28% |
| Nov 13, 2023 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 200 | $17.61 | $3.5K | 561,270 |
| Nov 3, 2023 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 10,541 | $15.26 | $160.8K | 565,343 |
| Nov 2, 2023 | Harmon Cyrus | Sell | 30,000 | $12.65 | $379.4K | 948,714 | |
| Oct 3, 2023 | Harmon Cyrus | Sell | 25,000 | $12.41 | $310.3K | 973,714 | |
| Sep 21, 2023 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 20,000 | $12.67 | $253.4K | 572,011 |
| Sep 14, 2023 | BVF PARTNERS L P/IL | Director | Buy | 1,505,932 | $9.84 | $14.82M1.7% OS | 4,688,954+47% |
| Sep 5, 2023 | Harmon Cyrus | Sell | 25,000 | $10.26 | $256.6K | 1,008,714 | |
| Aug 17, 2023 | Harmon Cyrus | Sell | 15,000 | $10.14 | $152.1K | 1,023,714 | |
| Jun 9, 2023 | Harmon Cyrus | Sell | 10,000 | $6.30 | $63.0K | 1,038,714 | |
| Jun 7, 2023 | Harmon Cyrus | Sell | 10,000 | $6.17 | $61.7K | 1,053,714 | |
| Jun 14, 2022 | BVF PARTNERS L P/IL | Director | Buy | 200,000 | $4.03 | $806.9K | 3,913,676 |
| Mar 14, 2022 | Horn Kinney | CHIEF BUSINESS OFFICER | Sell | 5,253 | $4.75 | $25.0K | 2,458-68% |
Showing 1–50 of 71
1 / 2
OLMA Insider Buying Activity
The following table shows recent insider purchases of Olema Pharmaceuticals, Inc. (OLMA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 13, 2025 | Bain Capital Life Sciences Investors, LLC | Buy | 300,000 | $5.76 | $1.73M | 7,800,000 | |
| Dec 17, 2024 | Graham G. Walmsley | Director | Buy | 700,761 | $6.75 | $4.73M0.8% OS | 1,408,875+99% |
| Dec 18, 2023 | Graham G. Walmsley | Director | Buy | 640,000 | $10.74 | $6.87M0.7% OS | 1,800,000+55% |
| Dec 8, 2023 | Paradigm Biocapital Advisors LP | 10% Owner | Buy | 100,000 | $11.60 | $1.16M | 6,590,981 |
| Sep 14, 2023 | BVF PARTNERS L P/IL | Director | Buy | 1,505,932 | $9.84 | $14.82M1.7% OS | 4,688,954+47% |
| Jun 14, 2022 | BVF PARTNERS L P/IL | Director | Buy | 200,000 | $4.03 | $806.9K | 3,913,676 |
OLMA Insider Selling Activity
The following table shows recent insider sales of Olema Pharmaceuticals, Inc. (OLMA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | Mitchell Shawnte | officer: CHIEF LEGAL OFFICER | Sell | 39,767 | $23.78 | $945.8K | 233-99% |
| Jan 21, 2026 | Harmon Cyrus | director | Sell | 10,000 | $26.88 | $268.8K | 727,770 |
| Jan 16, 2026 | Harmon Cyrus | director | Sell | 3,489 | $29.12 | $101.6K | 737,770 |
| Jan 15, 2026 | Kovacs Shane William Charles | officer: CH. OPERATING & FINANCIAL OFF. | Sell | 103,822 | $28.70 | $2.98M | 239,727-30% |
| Jan 14, 2026 | Myles David C. | officer: CH. DISCOV. & NON-CLIN DEV OFF | Sell | 110,000 | $28.25 | $3.11M | 577,764 |
| Dec 29, 2025 | Harmon Cyrus | Sell | 2,881 | $28.53 | $82.2K | 741,259 | |
| Dec 23, 2025 | CLARK IAN T | Sell | 264,800 | $29.73 | $7.87M | 234,896-53% | |
| Dec 23, 2025 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 51,000 | $30.46 | $1.55M | 601,656 |
| Dec 23, 2025 | Zojwalla Naseem | Chief Medical Officer | Sell | 269,509 | $27.94 | $7.53M | 116,918-70% |
| Sep 18, 2025 | Harmon Cyrus | Sell | 25,000 | $8.19 | $204.8K | 754,140 | |
| Dec 17, 2024 | Graham G. Walmsley | Director | Sell | 700,761 | $6.75 | $4.73M0.8% OS | 0Exit |
| Dec 11, 2024 | Bohen Sean | PRESIDENT AND CEO | Sell | 109,502 | $9.01 | $986.4K | 298,836-27% |
| Dec 11, 2024 | Harmon Cyrus | Sell | 16,393 | $9.03 | $148.0K | 772,277 | |
| Dec 11, 2024 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 35,159 | $9.01 | $316.7K | 561,905 |
| Dec 11, 2024 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 26,066 | $9.01 | $234.9K | 611,947 |
| Dec 11, 2024 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Sell | 27,805 | $9.01 | $250.5K | 130,031 |
| Aug 5, 2024 | Paradigm Biocapital Advisors LP | 10% Owner | Sell | 2,400,000 | $14.92 | $35.80M2.8% OS | 4,720,482-34% |
| Jul 31, 2024 | Harmon Cyrus | Sell | 5,000 | $15.57 | $77.9K | 752,217 | |
| Jul 12, 2024 | Harmon Cyrus | Sell | 5,000 | $12.26 | $61.3K | 756,283 | |
| Jul 2, 2024 | Harmon Cyrus | Sell | 20,000 | $10.77 | $215.4K | 761,283 | |
| Jun 6, 2024 | Graham G. Walmsley | Director | Sell | 1,175,000 | $14.85 | $17.45M1.3% OS | 708,114-62% |
| Jun 4, 2024 | Harmon Cyrus | Sell | 25,000 | $10.30 | $257.4K | 791,283 | |
| May 7, 2024 | Harmon Cyrus | Sell | 5,000 | $10.92 | $54.6K | 806,283 | |
| May 2, 2024 | Harmon Cyrus | Sell | 15,000 | $9.51 | $142.7K | 811,283 | |
| Mar 29, 2024 | Harmon Cyrus | Sell | 20,000 | $10.97 | $219.4K | 826,283 | |
| Mar 4, 2024 | Harmon Cyrus | Sell | 25,000 | $12.41 | $310.3K | 846,383 | |
| Feb 2, 2024 | Harmon Cyrus | Sell | 30,000 | $12.79 | $383.6K | 876,283 | |
| Jan 2, 2024 | Harmon Cyrus | Sell | 25,000 | $13.38 | $334.5K | 903,783 | |
| Dec 1, 2023 | Harmon Cyrus | Sell | 25,000 | $12.57 | $314.3K | 926,283 | |
| Nov 22, 2023 | Bohen Sean | PRESIDENT AND CEO | Sell | 57,225 | $14.40 | $824.1K | 175,459 |
| Nov 22, 2023 | Harmon Cyrus | Sell | 8,181 | $14.39 | $117.7K | 955,272 | |
| Nov 22, 2023 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Sell | 18,742 | $14.39 | $269.7K | 434,832 |
| Nov 22, 2023 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 13,629 | $14.40 | $196.2K | 580,952 |
| Nov 22, 2023 | Zojwalla Naseem | CHIEF MEDICAL OFFICER | Sell | 14,556 | $14.38 | $209.3K | 37,959-28% |
| Nov 13, 2023 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 200 | $17.61 | $3.5K | 561,270 |
| Nov 3, 2023 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 10,541 | $15.26 | $160.8K | 565,343 |
| Nov 2, 2023 | Harmon Cyrus | Sell | 30,000 | $12.65 | $379.4K | 948,714 | |
| Oct 3, 2023 | Harmon Cyrus | Sell | 25,000 | $12.41 | $310.3K | 973,714 | |
| Sep 21, 2023 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Sell | 20,000 | $12.67 | $253.4K | 572,011 |
| Sep 5, 2023 | Harmon Cyrus | Sell | 25,000 | $10.26 | $256.6K | 1,008,714 | |
| Aug 17, 2023 | Harmon Cyrus | Sell | 15,000 | $10.14 | $152.1K | 1,023,714 | |
| Jun 9, 2023 | Harmon Cyrus | Sell | 10,000 | $6.30 | $63.0K | 1,038,714 | |
| Jun 7, 2023 | Harmon Cyrus | Sell | 10,000 | $6.17 | $61.7K | 1,053,714 | |
| Mar 14, 2022 | Horn Kinney | CHIEF BUSINESS OFFICER | Sell | 5,253 | $4.75 | $25.0K | 2,458-68% |
OLMA Insiders
Kovacs Shane William Charles
officer: CH. OPERATING & FINANCIAL OFF.
Sold $3.57M
3 tradesLast: Jan 15, 2026
Similar Stocks to OLMA
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B